Related references
Note: Only part of the references are listed.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
Yushun Wan et al.
JOURNAL OF VIROLOGY (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Convalescent plasma as a potential therapy for COVID-19
Long Chen et al.
LANCET INFECTIOUS DISEASES (2020)
A new coronavirus associated with human respiratory disease in China
Fan Wu et al.
NATURE (2020)
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
Eva Schrezenmeier et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Emmie de Wit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Timothy P. Sheahan et al.
NATURE COMMUNICATIONS (2020)
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Markus Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade
B. Coutard et al.
ANTIVIRAL RESEARCH (2020)
SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
Carly G. K. Ziegler et al.
CELL (2020)
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Daniel Wrapp et al.
CELL (2020)
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Vanessa Monteil et al.
CELL (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Xueting Yao et al.
CLINICAL INFECTIOUS DISEASES (2020)
SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?
Gabriela M. Kuster et al.
EUROPEAN HEART JOURNAL (2020)
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Chi Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Chenguang Shen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
Calvin J. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Lisi Deng et al.
JOURNAL OF INFECTION (2020)
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Jianjun Gao et al.
BIOSCIENCE TRENDS (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
Markus Hoffmann et al.
MOLECULAR CELL (2020)
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
Jia Liu et al.
CELL DISCOVERY (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Leon Caly et al.
ANTIVIRAL RESEARCH (2020)
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology
Arianna Pani et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial
Ling Li et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
STEROID IS FIRST DRUG SHOWN TO PREVENT DEATHS FROM COVID-19
Heidi Ledford
NATURE (2020)
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
Georgi Momekov et al.
BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT (2020)
A real-time dashboard of clinical trials for COVID-19
Kristian Thorlund et al.
LANCET DIGITAL HEALTH (2020)
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
Henning Ulrich et al.
STEM CELL REVIEWS AND REPORTS (2020)
Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
Jaegyun Lim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2020)
SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?
Gabriela M. Kuster et al.
EUROPEAN HEART JOURNAL (2020)
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
Guangyu Zhou et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
Juan Meng et al.
EMERGING MICROBES & INFECTIONS (2020)
Nucleoside analogues for the treatment of coronavirus infections
Andrea J. Pruijssers et al.
CURRENT OPINION IN VIROLOGY (2019)
Therapeutic strategies to target the Ebola virus life cycle
Thomas Hoenen et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
Maria L. Agostini et al.
JOURNAL OF VIROLOGY (2019)
Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
Francois Ferron et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape
Lingshu Wang et al.
JOURNAL OF VIROLOGY (2018)
Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models
Ji-Ae Kim et al.
VIRUSES-BASEL (2018)
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini et al.
MBIO (2018)
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques
Jeremie Guedj et al.
PLOS MEDICINE (2018)
Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
Rameshwar U. Kadam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade
Vijayakumar Sukumaran et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
SARS and MERS: recent insights into emerging coronaviruses
Emmie de Wit et al.
NATURE REVIEWS MICROBIOLOGY (2016)
The Viral Polymerase Inhibitor 7-Deaza-2′-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model
Joanna Zmurko et al.
PLOS NEGLECTED TROPICAL DISEASES (2016)
Azithromycin for the Prevention of COPD Exacerbations: The Good, Bad, and Ugly
Stephanie Parks Taylor et al.
AMERICAN JOURNAL OF MEDICINE (2015)
Broad-spectrum antivirals against viral fusion
Frederic Vigant et al.
NATURE REVIEWS MICROBIOLOGY (2015)
Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
Jean Kaoru Millet et al.
VIRUS RESEARCH (2015)
Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection
Allison L. Totura et al.
MBIO (2015)
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
John Mair-Jenkins et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies
Fang Li
JOURNAL OF VIROLOGY (2015)
Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
Adriaan H. de Wilde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
Lisa Oestereich et al.
ANTIVIRAL RESEARCH (2014)
Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model
Sophie J. Smither et al.
ANTIVIRAL RESEARCH (2014)
Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral
Leen Delang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin
M. Y. F. Tay et al.
ANTIVIRAL RESEARCH (2013)
Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication
Lindsay Lundberg et al.
ANTIVIRAL RESEARCH (2013)
Inhibition of novel β coronavirus replication by a combination of interferon- α2b and ribavirin
Darryl Falzarano et al.
SCIENTIFIC REPORTS (2013)
Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics
Everett Clinton Smith et al.
PLOS PATHOGENS (2013)
Favipiravir (T-705) inhibits in vitro norovirus replication
J. Rocha-Pereira et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus
Kylie M. Wagstaff et al.
BIOCHEMICAL JOURNAL (2012)
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Ali Moh Zaki et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Azithromycin induces anti-viral responses in bronchial epithelial cells
V. Gielen et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2
Shutoku Matsuyama et al.
JOURNAL OF VIROLOGY (2010)
Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
Sandrine Belouzard et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Arbidol: A broad-spectrum antiviral compound that blocks viral fusion
Y. S. Boriskin et al.
CURRENT MEDICINAL CHEMISTRY (2008)
The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice
Yumiko Imai et al.
EXPERIMENTAL PHYSIOLOGY (2008)
Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants
Zubair H. Aghai et al.
PEDIATRIC RESEARCH (2007)
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
Zhongyu Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
Dale L. Barnard et al.
ANTIVIRAL RESEARCH (2006)
Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital
KM Yeh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
JJ Feld et al.
NATURE (2005)
Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
J Paragas et al.
ANTIVIRAL RESEARCH (2005)
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies
YX He et al.
JOURNAL OF IMMUNOLOGY (2005)
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice
TC Greenough et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J. Vincent et al.
VIROLOGY JOURNAL (2005)
Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale
JD Berry
VETERINARY JOURNAL (2005)
Use of convalescent plasma therapy in SARS patients in Hong Kong
Y Cheng et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)
Severe acute respiratory syndrome related coronavirus is inhibited by interferon-α
U Ströher et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
JH Sui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Interferon-β 1a and SARS coronavirus replication
LE Hensley et al.
EMERGING INFECTIOUS DISEASES (2004)
Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and Chlomydio pneumoniae
JJM Bouwman et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2004)
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
N Yamamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients
H Hofmann et al.
JOURNAL OF VIROLOGY (2004)
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
E Keyaerts et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Treatment of SARS with human interferons
J Cinatl et al.
LANCET (2003)
A novel coronavirus associated with severe acute respiratory syndrome
TG Ksiazek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
In vitro and in vivo activities of anti-influenza virus compound T-705
Y Furuta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
High-density miniaturized thermal shift assays as a general strategy for drug discovery
MW Pantoliano et al.
JOURNAL OF BIOMOLECULAR SCREENING (2001)
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
S Crotty et al.
NATURE MEDICINE (2000)
Influenza virus neuraminidase inhibitors
LV Gubareva et al.
LANCET (2000)
Share Paper
